<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Allergy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Allergy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский Аллергологический Журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1810-8830</issn><issn publication-format="electronic">2686-682X</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1588</article-id><article-id pub-id-type="doi">10.36691/RJA1588</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Case reports</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Клинические случаи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">The significance of component-resolved allergy diagnostics in atopic dermatitis patients when prescribing allergen-specific immunotherapy</article-title><trans-title-group xml:lang="ru"><trans-title>Значимость компонентной аллергодиагностики в определении показаний к аллергенспецифической иммунотерапии у больных атопическим дерматитом</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4609-2591</contrib-id><contrib-id contrib-id-type="spin">9567-1894</contrib-id><name-alternatives><name xml:lang="en"><surname>Elisyutina</surname><given-names>Olga G.</given-names></name><name xml:lang="ru"><surname>Елисютина</surname><given-names>Ольга Гурьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>д.м.н.</p></bio><email>el-olga@yandex.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3358-5087</contrib-id><contrib-id contrib-id-type="spin">5012-7242</contrib-id><name-alternatives><name xml:lang="en"><surname>Fedenko</surname><given-names>Elena S.</given-names></name><name xml:lang="ru"><surname>Феденко</surname><given-names>Елена Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), Professor</p></bio><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><email>efedks@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1302-4178</contrib-id><contrib-id contrib-id-type="spin">4874-8100</contrib-id><name-alternatives><name xml:lang="en"><surname>Smolnikov</surname><given-names>Eugeniy V.</given-names></name><name xml:lang="ru"><surname>Смольников</surname><given-names>Евгений Валентинович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>qwertil2010@yandex.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5021-9276</contrib-id><contrib-id contrib-id-type="spin">2337-7930</contrib-id><name-alternatives><name xml:lang="en"><surname>Litovkina</surname><given-names>Alla O.</given-names></name><name xml:lang="ru"><surname>Литовкина</surname><given-names>Алла Олеговна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>dr.litovkina@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8254-9715</contrib-id><contrib-id contrib-id-type="spin">4146-1788</contrib-id><name-alternatives><name xml:lang="en"><surname>Shtyrbul</surname><given-names>Olga V.</given-names></name><name xml:lang="ru"><surname>Штырбул</surname><given-names>Ольга Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>к.м.н.</p></bio><email>ovs-495@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">National Research Center ― Institute of Immunology</institution></aff><aff><institution xml:lang="ru">Государственный научный центр «Институт иммунологии»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Peoples’ Friendship University of Russia</institution></aff><aff><institution xml:lang="ru">Российский университет дружбы народов</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2022-12-20" publication-format="electronic"><day>20</day><month>12</month><year>2022</year></pub-date><pub-date date-type="pub" iso-8601-date="2022-12-05" publication-format="electronic"><day>05</day><month>12</month><year>2022</year></pub-date><volume>19</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>519</fpage><lpage>533</lpage><history><date date-type="received" iso-8601-date="2022-12-06"><day>06</day><month>12</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-12-12"><day>12</day><month>12</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, Pharmarus Print Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, Фармарус Принт Медиа</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">Pharmarus Print Media</copyright-holder><copyright-holder xml:lang="ru">Фармарус Принт Медиа</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2025-01-05"/></permissions><self-uri xlink:href="https://rusalljournal.ru/raj/article/view/1588">https://rusalljournal.ru/raj/article/view/1588</self-uri><abstract xml:lang="en"><p>The paper presents clinical cases of patients with severe atopic dermatitis with polyvalent sensitization in an adult patient and in a pediatric patient. Standard topical and systemic therapy proved to be an insufficiently effective strategy in these patients. Both patients underwent component-resolved allergy diagnostics, which made it possible to identify the causally significant components of allergens, sensitization to which affects the course of atopic dermatitis. On the basis of the survey, indications for allergen-specific immunotherapy with causally significant allergens were determined. The treatment made it possible to achieve non-drug remission not only of atopic dermatitis but also of concomitant respiratory allergic diseases.</p> <p>The cases demonstrate the efficacy and safety of allergen-specific immunotherapy in patients with proven sensitization to causally significant allergens based on component allergy diagnostics.</p></abstract><trans-abstract xml:lang="ru"><p>В статье представлены два клинических случая пациентов с атопическим дерматитом тяжёлого течения в сочетании с поливалентной сенсибилизацией, у которых стандартная наружная и системная терапия оказались недостаточно эффективными. Обоим пациентам проведена компонентная аллергодиагностика, что позволило выявить причинно-значимые компоненты аллергенов, сенсибилизация к которым оказывает влияние на течение атопического дерматита. На основании обследования были определены показания к аллергенспецифической иммунотерапии причинно-значимыми аллергенами. Проведённое лечение позволило достичь немедикаментозной ремиссии не только атопического дерматита, но и сопутствующих респираторных аллергических заболеваний.</p> <p>Представленные нами случаи демонстрируют эффективность и безопасность аллергенспецифической иммунотерапии у пациентов с доказанной сенсибилизацией к причинно-значимым аллергенам на основании компонентной аллергодиагностики.</p></trans-abstract><kwd-group xml:lang="en"><kwd>atopic dermatitis</kwd><kwd>component-resolved allergy diagnostics</kwd><kwd>allergen specific immunotherapy</kwd><kwd>case reports</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>атопический дерматит</kwd><kwd>компонентная аллергодиагностика</kwd><kwd>аллергенспецифическая иммунотерапия</kwd><kwd>клинические случаи</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Khaitov RM. Immunology. 3rd edition, revised and updated. Moscow: GEOTAR-Media; 2018. 496 p. (In Russ).</mixed-citation><mixed-citation xml:lang="ru">Хаитов Р.М. Иммунология. 3-е изд., перераб. и доп. Москва: ГЭОТАР-Медиа, 2018. 496 с.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Federal clinical guidelines for the management of patients with atopic dermatitis. Moscow: Russian Society of Dermatovenerologists and Cosmetologists, Russian Association of Allergologists and Clinical Immunologists, Union of Pediatricians of Russia, National Alliance of Dermatovenerologists and Cosmetologists; 2021. Available from: https://cr.minzdrav.gov.ru/recomend/265_2. Accessed: 12.11.2022.</mixed-citation><mixed-citation xml:lang="ru">Федеральные клинические рекомендации по ведению больных атопическим дерматитом [электронный ресурс]. Москва: Российское общество дерматовенерологов и косметологов, Российская ассоциация аллергологов и клинических иммунологов, Союз педиатров России, Национальный альянс дерматовенерологов и косметологов, 2021. Режим доступа: https://cr.minzdrav.gov.ru/recomend/265_2. Дата обращения: 12.11.2022.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Wollenberg A, Christen-Zäch S, Taieb A, et al. European task force on atopic Dermatitis/EADV eczema task force. ETFAD/EADV eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717–2744. doi: 10.1111/jdv.16892</mixed-citation><mixed-citation xml:lang="ru">Wollenberg A., Christen-Zäch S., Taieb A., et al. European task force on atopic Dermatitis/EADV eczema task force. ETFAD/EADV eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children // J Eur Acad Dermatol Venereol. 2020. Vol. 34, N 12. Р. 2717–2744. doi: 10.1111/jdv.16892</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Ständer S. Atopic dermatitis. N Engl J Med. 2021;384(12): 1136–1143. doi: 10.1056/NEJMra2023911</mixed-citation><mixed-citation xml:lang="ru">Ständer S. Atopic dermatitis // N Engl J Med. 2021. Vol. 384, N 12. Р. 1136–1143. doi: 10.1056/NEJMra2023911</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Li H, Zhang Z, Zhang H, et al. Update on the Pathogenesis and therapy of atopic dermatitis. Clin Rev Allergy Immunol. 2021; 61(3):324–338. doi: 10.1007/s12016-021-08880-3</mixed-citation><mixed-citation xml:lang="ru">Li H., Zhang Z., Zhang H., et al. Update on the pathogenesis and therapy of atopic dermatitis // Clin Rev Allergy Immunol. 2021. Vol. 61, N 3. Р. 324–338. doi: 10.1007/s12016-021-08880-3</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Sabat R, Wolk K, Loyal L, et al. T cell pathology in skin inflammation. Semin Immunopathol. 2019;41(3):359–377. doi: 10.1007/s00281-019-00742-7</mixed-citation><mixed-citation xml:lang="ru">Sabat R., Wolk K., Loyal L., et al. T cell pathology in skin inflammation // Semin Immunopathol. 2019. Vol. 41, N 3. Р. 359–377. doi: 10.1007/s00281-019-00742-7</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Yang L, Fu J, Zhou Y. Research progress in atopic march. Front Immunol. 2020;(11):1907. doi: 10.3389/fimmu.2020.01907</mixed-citation><mixed-citation xml:lang="ru">Yang L, Fu J, Zhou Y. Research progress in atopic march // Front Immunol. 2020. N 11. Р. 1907. doi: 10.3389/fimmu.2020.01907</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Paller AS, Spergel JM, Mina-Osorio P, Irvine AD. The atopic march and atopic multimorbidity: Many trajectories, many pathways. J Allergy Clin Immunol. 2019;143(1):46–55. doi: 10.1016/j.jaci.2018.11.006</mixed-citation><mixed-citation xml:lang="ru">Paller A.S., Spergel J.M., Mina-Osorio P., Irvine AD. The atopic march and atopic multimorbidity: Many trajectories, many pathways // J Allergy Clin Immunol. 2019. Vol. 143, N 1. Р. 46–55. doi: 10.1016/j.jaci.2018.11.006</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Roduit C, Frei R, Depner M, et al. Phenotypes of atopic dermatitis depending on the timing of onset and progression in childhood. JAMA Pediatr. 2017;171(7):655–662. doi: 10.1001/jamapediatrics.2017.0556</mixed-citation><mixed-citation xml:lang="ru">Roduit C., Frei R., Depner M., et al. Phenotypes of atopic dermatitis depending on the timing of onset and progression in childhood // JAMA Pediatr. 2017. Vol. 171, N 7. Р. 655–662. doi: 10.1001/jamapediatrics.2017.0556</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023): 1109–1122. doi: 10.1016/S0140-6736(15)00149-X</mixed-citation><mixed-citation xml:lang="ru">Weidinger S., Novak N. Atopic dermatitis // Lancet. 2016. Vol. 387, N 10023. Р. 1109–1122. doi: 10.1016/S0140-6736(15)00149-X</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">David Boothe W, Tarbox JA, Tarbox MB. Atopic dermatitis: pathophysiology. Adv Exp Med Biol. 2017;(1027):21–37. doi: 10.1007/978-3-319-64804-0_3</mixed-citation><mixed-citation xml:lang="ru">David Boothe W., Tarbox J.A., Tarbox M.B. Atopic dermatitis: pathophysiology // Adv Exp Med Biol. 2017. N 1027. Р. 21–37. doi: 10.1007/978-3-319-64804-0_3</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Anto JM, Bousquet J, Akdis M, et al. Mechanisms of the development of allergy (MeDALL): Introducing novel concepts in allergy phenotypes. J Allergy Clin Immunol. 2017;139(2):388–399. doi: 10.1016/j.jaci.2016.12.940</mixed-citation><mixed-citation xml:lang="ru">Anto J.M., Bousquet J., Akdis M., et al. Mechanisms of the development of allergy (MeDALL): Introducing novel concepts in allergy phenotypes // J Allergy Clin Immunol. 2017. Vol. 139, N 2. Р. 388–399. doi: 10.1016/j.jaci.2016.12.940</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Matricardi PM, Kleine-Tebbe J, Hoffmann HJ, et al. EAACI molecular allergology user’s guide. Pediatr Allergy Immunol. 2016; 27(Suppl 23):1–250. doi: 10.1111/pai.12563</mixed-citation><mixed-citation xml:lang="ru">Matricardi P.M., Kleine-Tebbe J., Hoffmann H.J., et al. EAACI molecular allergology user’s guide // Pediatr Allergy Immunol. 2016. Vol. 27, Suppl. 23. Р. 1–250. doi: 10.1111/pai.12563</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Alvaro-Lozano M, Akdis CA, Akdis M, et al. EAACI allergen immunotherapy user’s guide. Pediatr Allergy Immunol. 2020; 31(Suppl 25):1–101. doi: 10.1111/pai.13189</mixed-citation><mixed-citation xml:lang="ru">Alvaro-Lozano M., Akdis C.A., Akdis M., et al. EAACI allergen immunotherapy user’s guide // Pediatr Allergy Immunol. 2020. Vol. 31, Suppl. 25. Р. 1–101. doi: 10.1111/pai.13189</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Seegräber M, Srour J, Walter A, et al. Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol. 2018;11(5):467–474. doi: 10.1080/17512433.2018.1449642</mixed-citation><mixed-citation xml:lang="ru">Seegräber M., Srour J., Walter A., et al. Dupilumab for treatment of atopic dermatitis // Expert Rev Clin Pharmacol. 2018. Vol. 11, N 5. Р. 467–474. doi: 10.1080/17512433.2018.1449642</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Nezamololama N, Fieldhouse K, Metzger K, Gooderham M. Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: A review of abrocitinib, baricitinib, and upadacitinib. Drugs Context. 2020;9:2020-8-5. doi: 10.7573/dic.2020-8-5</mixed-citation><mixed-citation xml:lang="ru">Nezamololama N., Fieldhouse K., Metzger K., Gooderham M. Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib // Drugs Context. 2020. Vol. 9. Р. 2020-8-5. doi: 10.7573/dic.2020-8-5</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Ferreira S, Guttman-Yassky E, Torres T. Selective JAK1 inhibitors for the treatment of atopic dermatitis: Focus on upadacitinib and abrocitinib. Am J Clin Dermatol. 2020;21(6):783–798. doi: 10.1007/s40257-020-00548-6</mixed-citation><mixed-citation xml:lang="ru">Ferreira S., Guttman-Yassky E., Torres T. Selective JAK1 inhibitors for the treatment of atopic dermatitis: Focus on upadacitinib and abrocitinib // Am J Clin Dermatol. 2020. Vol. 21, N 6. Р. 783–798. doi: 10.1007/s40257-020-00548-6</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Simpson EL, Bieber T, Guttman-Yassky E, et al.; SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348. doi: 10.1056/NEJMoa1610020</mixed-citation><mixed-citation xml:lang="ru">Simpson E.L., Bieber T., Guttman-Yassky E., et al.; SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis // N Engl J Med. 2016. Vol. 375, N 24. Р. 2335–2348. doi: 10.1056/NEJMoa1610020</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Traidl S, Freimooser S, Werfel T. Janus kinase inhibitors for the therapy of atopic dermatitis. Allergol Select. 2021;(5):293–304. doi: 10.5414/ALX02272E</mixed-citation><mixed-citation xml:lang="ru">Traidl S., Freimooser S., Werfel T. Janus kinase inhibitors for the therapy of atopic dermatitis // Allergol Select. 2021. N 5. Р. 293–304. doi: 10.5414/ALX02272E</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">Traidl S, Roesner L, Zeitvogel J, Werfel T. Eczema herpeticum in atopic dermatitis. Allergy. 2021;76(10):3017–3027. doi: 10.1111/all.14853</mixed-citation><mixed-citation xml:lang="ru">Traidl S., Roesner L., Zeitvogel J., Werfel T. Eczema herpeticum in atopic dermatitis // Allergy. 2021. Vol. 76, N 10. Р. 3017–3027. doi: 10.1111/all.14853</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">Silverberg JI, Thyssen JP, Fahrbach K, et al. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: A systematic literature review and network meta-analysis. J Eur Acad Dermatol Venereol. 2021;35(9):1797–1810. doi: 10.1111/jdv.17351</mixed-citation><mixed-citation xml:lang="ru">Silverberg J.I., Thyssen J.P., Fahrbach K., et al. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: A systematic literature review and network meta-analysis // J Eur Acad Dermatol Venereol. 2021. Vol. 35, N 9. Р. 1797–1810. doi: 10.1111/jdv.17351</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">Paller A, Jaworski JC, Simpson EL, et al. Major comorbidities of atopic dermatitis: beyond allergic disorders. Am J Clin Dermatol. 2018;19(6):821–838. doi: 10.1007/s40257-018-0383-4</mixed-citation><mixed-citation xml:lang="ru">Paller A., Jaworski J.C., Simpson E.L., et al. Major comorbidities of atopic dermatitis: Beyond allergic disorders // Am J Clin Dermatol. 2018. Vol. 19, N 6. Р. 821–838. doi: 10.1007/s40257-018-0383-4</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">Traidl S, Werfel T. [Allergen immunotherapy for atopic dermatitis]. Hautarzt. 2021;72(12):1103–1112. (In German). doi: 10.1007/s00105-021-04909-y</mixed-citation><mixed-citation xml:lang="ru">Traidl S., Werfel T. [Allergen immunotherapy for atopic dermatitis] // Hautarzt. 2021. Vol. 72, N 12. Р. 1103–1112. (In German). doi: 10.1007/s00105-021-04909-y</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">Lee J, Park CO, Lee KH. Specific immunotherapy in atopic dermatitis. Allergy Asthma Immunol Res. 2015;7(3):221–229. doi: 10.4168/aair.2015.7.3.221</mixed-citation><mixed-citation xml:lang="ru">Lee J., Park C.O., Lee K.H. Specific immunotherapy in atopic dermatitis // Allergy Asthma Immunol Res. 2015. Vol. 7, N 3. Р. 221–229. doi: 10.4168/aair.2015.7.3.221</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">Głobińska A, Boonpiyathad T, Satitsuksanoa P, et al. Mechanisms of allergen-specific immunotherapy: Diverse mechanisms of immune tolerance to allergens. Ann Allergy Asthma Immunol. 2018; 121(3):306–312. doi: 10.1016/j.anai.2018.06.026</mixed-citation><mixed-citation xml:lang="ru">Głobińska A., Boonpiyathad T., Satitsuksanoa P., et al. Mechanisms of allergen-specific immunotherapy: Diverse mechanisms of immune tolerance to allergens // Ann Allergy Asthma Immunol. 2018. Vol. 121, N 3. Р. 306–312. doi: 10.1016/j.anai.2018.06.026</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">Halken S, Larenas-Linnemann D, Roberts G, et al. EAACI guidelines on allergen immunotherapy: Prevention of allergy. Pediatr Allergy Immunol. 2017;28(8):728–745. doi: 10.1111/pai.12807</mixed-citation><mixed-citation xml:lang="ru">Halken S., Larenas-Linnemann D., Roberts G., et al. EAACI guidelines on allergen immunotherapy: Prevention of allergy // Pediatr Allergy Immunol. 2017. Vol. 28, N 8. Р. 728–745. doi: 10.1111/pai.12807</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">Gushchin IS, Kurbacheva OM. Allergen-specific immunotherapy. Allergology immunology. 2001;2(2):73. (In Russ).</mixed-citation><mixed-citation xml:lang="ru">Гущин И.С., Курбачева О.М. Aллергенспецифическая иммунотерапия // Аллергология и иммунология. 2001. Т. 2, № 2. С. 73.</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><citation-alternatives><mixed-citation xml:lang="en">Novak N. Allergen specific immunotherapy for atopic dermatitis. Curr Opin Allergy Clin Immunol. 2007;7(6):542–546. doi: 10.1097/ACI.0b013e3282f1d66c</mixed-citation><mixed-citation xml:lang="ru">Novak N. Allergen specific immunotherapy for atopic dermatitis // Curr Opin Allergy Clin Immunol. 2007. Vol. 7, N 6. Р. 542–546. doi: 10.1097/ACI.0b013e3282f1d66c</mixed-citation></citation-alternatives></ref><ref id="B29"><label>29.</label><citation-alternatives><mixed-citation xml:lang="en">Zhong H, Deng X, Song Z, et al. Immunological changes after ASIT in AD allergen-specific immunotherapy and their potential correlation with clinical response in patients with atopic dermatitis patients sensitized to house dust mite. J Eur Acad Dermatol Venereol. 2015;29(7):1318–1324. doi: 10.1111/jdv.12813</mixed-citation><mixed-citation xml:lang="ru">Zhong H., Deng X., Song Z., et al. Immunological changes after ASIT in AD allergen-specific immunotherapy and their potential correlation with clinical response in patients with atopic dermatitis patients sensitized to house dust mite // J Eur Acad Dermatol Venereol. 2015. Vol. 29, N 7. Р. 1318–1324. doi: 10.1111/jdv.12813</mixed-citation></citation-alternatives></ref><ref id="B30"><label>30.</label><citation-alternatives><mixed-citation xml:lang="en">Hajdu K, Kapitány A, Dajnoki Z, et al. Improvement of clinical and immunological parameters after allergen-specific immunotherapy in atopic dermatitis. J Eur Acad Dermatol Venereol. 2021;35(6): 1357–1361. doi: 10.1111/jdv.17018</mixed-citation><mixed-citation xml:lang="ru">Hajdu K., Kapitány A., Dajnoki Z., et al. Improvement of clinical and immunological parameters after allergen-specific immunotherapy in atopic dermatitis // J Eur Acad Dermatol Venereol. 2021. Vol. 35, N 6. Р. 1357–1361. doi: 10.1111/jdv.17018</mixed-citation></citation-alternatives></ref><ref id="B31"><label>31.</label><citation-alternatives><mixed-citation xml:lang="en">Kiatiwat P, Mitthamsiri W, Boonpiyathad T, et al. Successful treatment of atopic dermatitis with house dust mite sublingual immunotherapy tablets. Asian Pac J Allergy Immunol. 2021. doi: 10.12932/AP-231120-1004</mixed-citation><mixed-citation xml:lang="ru">Kiatiwat P., Mitthamsiri W., Boonpiyathad T., et al. Successful treatment of atopic dermatitis with house dust mite sublingual immunotherapy tablets // Asian Pac J Allergy Immunol. 2021. doi: 10.12932/AP-231120-1004</mixed-citation></citation-alternatives></ref><ref id="B32"><label>32.</label><citation-alternatives><mixed-citation xml:lang="en">Fedenko E, Elisyutina O, Shtyrbul O, et al. Microarray-based IgE serology improves management of severe atopic dermatitis in two children. Pediatr Allergy Immunol. 2016;27(6):645–649. doi: 10.1111/pai.12572</mixed-citation><mixed-citation xml:lang="ru">Fedenko E., Elisyutina O., Shtyrbul O., et al. Microarray-based IgE serology improves management of severe atopic dermatitis in two children // Pediatr Allergy Immunol. 2016. Vol. 27, N 6. Р. 645–649. doi: 10.1111/pai.12572</mixed-citation></citation-alternatives></ref><ref id="B33"><label>33.</label><citation-alternatives><mixed-citation xml:lang="en">Pellefigues C. IgE autoreactivity in atopic dermatitis: Paving the road for autoimmune diseases? Antibodies (Basel). 2020;9(3):47. doi: 10.3390/antib9030047</mixed-citation><mixed-citation xml:lang="ru">Pellefigues C. IgE autoreactivity in atopic dermatitis: paving the road for autoimmune diseases? // Antibodies (Basel). 2020. Vol. 9, N 3. Р. 47. doi: 10.3390/antib9030047</mixed-citation></citation-alternatives></ref><ref id="B34"><label>34.</label><citation-alternatives><mixed-citation xml:lang="en">Breiteneder H, Peng YQ, Agache I, et al. Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma. Allergy. 2020;75(12):3039–3068. doi: 10.1111/all.14582</mixed-citation><mixed-citation xml:lang="ru">Breiteneder H., Peng Y.Q., Agache I., et al. Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma // Allergy. 2020. Vol. 75, N 12. Р. 3039–3068. doi: 10.1111/all.14582</mixed-citation></citation-alternatives></ref><ref id="B35"><label>35.</label><citation-alternatives><mixed-citation xml:lang="en">Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: Part I ― systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409–1431. doi: 10.1111/jdv.18345</mixed-citation><mixed-citation xml:lang="ru">Wollenberg A., Kinberger M., Arents B., et al. European guideline (EuroGuiDerm) on atopic eczema: Part I ― systemic therapy // J Eur Acad Dermatol Venereol. 2022. Vol. 36, N 9. Р. 1409–1431. doi: 10.1111/jdv.18345</mixed-citation></citation-alternatives></ref></ref-list></back></article>
